Difficulty: Medium
Average Score: 68%
Practice
In the treatment of diarrhea-associated hemolytic-uremic syndrome, one of the following options has no beneficial role
Correct answer
D
Rationale
In the treatment of diarrhea-associated hemolytic-uremic syndrome, the option that has no beneficial role is red cell transfusions (Option D).
The correct answer is D because red cell transfusions do not address the underlying cause of hemolytic-uremic syndrome, which is primarily related to kidney damage secondary to the release of toxins from certain strains of E. coli bacteria. Transfusions do not remove these toxins or treat the kidney damage.
Option A, dialysis, is beneficial in managing the complications of kidney failure that can occur in hemolytic-uremic syndrome. Option B, early intravenous volume expansion, helps maintain adequate renal perfusion and prevent further kidney damage. Option C, controlling hypertension, is important as high blood pressure can worsen kidney function.
In an educational context, understanding the rationale behind each treatment option is crucial for nurses and healthcare providers caring for pediatric patients with hemolytic-uremic syndrome. This knowledge can guide appropriate interventions, improve patient outcomes, and prevent potential complications. It also highlights the importance of evidence-based practice in pharmacological management.
The correct answer is D because red cell transfusions do not address the underlying cause of hemolytic-uremic syndrome, which is primarily related to kidney damage secondary to the release of toxins from certain strains of E. coli bacteria. Transfusions do not remove these toxins or treat the kidney damage.
Option A, dialysis, is beneficial in managing the complications of kidney failure that can occur in hemolytic-uremic syndrome. Option B, early intravenous volume expansion, helps maintain adequate renal perfusion and prevent further kidney damage. Option C, controlling hypertension, is important as high blood pressure can worsen kidney function.
In an educational context, understanding the rationale behind each treatment option is crucial for nurses and healthcare providers caring for pediatric patients with hemolytic-uremic syndrome. This knowledge can guide appropriate interventions, improve patient outcomes, and prevent potential complications. It also highlights the importance of evidence-based practice in pharmacological management.